Pfizer subsidiaries

Hospira, Inc. is the provider of injectable drugs and infusion technologies. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. The company is headquartered in Lake Forest, Ill., and has approximately 16,000 employees.

Monarch Pharmaceuticals, Inc. develops, manufactures, markets, and sells branded prescription pharmaceutical products and animal health products. The company was founded in 1994 and is based in Bristol, Tennessee. Monarch Pharmaceuticals, Inc. operates as a subsidiary of Pfizer Inc.

Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular and metabolic diseases. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high-density lipoprotein, or HDL, function.

Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer. As of December 31, 2011, it completed a Phase III trial in the latest stage. The Company's three subsidiaries include Medivation Prostate Therapeutics, Inc. (MPT), Medivation Neurology, Inc. (MNI) and Medivation Technologies, Inc. (MTI). MPT holds the Company's MDV300 series technology, which is in development for the treatment of advanced prostate cancer, and MTI holds its earlier stage technologies. MNI holds its dimebon technology, which was in development for the treatment of Alzheimer's disease and Huntington disease.

Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. It develops ICA-105665 that is in Phase I single dose escalation study in healthy volunteers for epilepsy and neuropathic pain; and Senicapoc, which is in Phase I multiple dose study in healthy volunteers for the treatment of asthma. The company also conducts ongoing drug discovery programs on new therapeutics for pain and inflammatory disorders. Icagen has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma, Inc.; and Pfizer, Inc.

Pharmacia was a pharmaceutical and biotechnological company in Sweden that merged with the American pharmaceutical company Upjohn in 1995.

Information on Meridian Medical Technologies, Inc., who has been putting emergency care treatment options into the hands of military and civilian defenders for more than 50 years.

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company's primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.

Barre Parent Corp. operates as a subsidiary of Pfizer Inc.

Founded in 1993, Greenstone LLC is a wholly owned subsidiary of Pfizer Inc-the world's largest research-based pharmaceutical company.1 The mission we share at Greenstone is to leverage our expertise to provide reliable, quality generic medications and exceptional value to our customers.

Coley Pharmaceutical Group operates as a biopharmaceutical company developing therapeutics and drug candidates that direct the human immune system to fight cancers, asthma and allergy, autoimmune disorders, and to enhance the effectiveness of vaccines. The company was formerly known as CpG ImmunoPharmaceuticals, Inc. and in August 2000 it changed its name to Coley Pharmaceutical Group, Inc. The company was founded in 1997 and is based in Wellesley, Massachusetts. As of December 28, 2007, Coley Pharmaceutical Group, Inc. operates as a subsidiary of Pfizer Inc.